Key Points
- CEO Roger Susi sold 3,089 shares of iRadimed stock for about $261,144 at an average price of $84.54. The sale was made under a pre-arranged Rule 10b5-1 trading plan, and he still directly owns more than 2.18 million shares.
- iRadimed recently beat earnings expectations, reporting $0.49 EPS versus the $0.46 consensus and revenue of $21.98 million versus $21.32 million expected. The company also issued guidance for FY 2026 and Q2 2026.
- The company announced a quarterly dividend of $0.20 per share, payable May 29, with a 0.9% annualized yield. Analysts remain constructive on the stock, with a consensus Buy rating and an average price target of $120.00.
iRadimed Corporation (NASDAQ:IRMD - Get Free Report) CEO Roger Susi sold 3,089 shares of iRadimed stock in a transaction that occurred on Monday, May 11th. The shares were sold at an average price of $84.54, for a total value of $261,144.06. Following the sale, the chief executive officer directly owned 2,184,411 shares in the company, valued at $184,670,105.94. This trade represents a 0.14% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
iRadimed Price Performance
IRMD stock opened at $85.27 on Thursday. iRadimed Corporation has a 1-year low of $50.88 and a 1-year high of $107.90. The business has a 50 day simple moving average of $94.40 and a two-hundred day simple moving average of $94.67. The company has a market capitalization of $1.09 billion, a price-to-earnings ratio of 46.60 and a beta of 0.90.
iRadimed (NASDAQ:IRMD - Get Free Report) last released its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, topping the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to the consensus estimate of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Sell-side analysts anticipate that iRadimed Corporation will post 1.52 EPS for the current fiscal year.
iRadimed Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Stockholders of record on Friday, May 15th will be given a dividend of $0.20 per share. The ex-dividend date is Friday, May 15th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.9%. iRadimed's dividend payout ratio (DPR) is presently 43.72%.
Wall Street Analysts Forecast Growth
A number of brokerages recently commented on IRMD. Lake Street Capital reissued a "buy" rating and set a $120.00 price target on shares of iRadimed in a research note on Wednesday, February 11th. Weiss Ratings upgraded iRadimed from a "buy (b-)" rating to a "buy (b)" rating in a research report on Wednesday, May 6th. Freedom Capital raised shares of iRadimed to a "strong-buy" rating in a report on Thursday, April 2nd. Finally, Roth Mkm restated a "buy" rating and issued a $120.00 price target on shares of iRadimed in a research report on Tuesday, February 10th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $120.00.
View Our Latest Analysis on iRadimed
Institutional Investors Weigh In On iRadimed
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. SG Americas Securities LLC boosted its position in shares of iRadimed by 88.6% during the fourth quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider's stock valued at $6,848,000 after buying an additional 33,072 shares during the period. Principal Financial Group Inc. purchased a new stake in iRadimed in the third quarter worth $422,000. Tudor Investment Corp ET AL purchased a new stake in iRadimed in the third quarter worth $666,000. RFG Advisory LLC bought a new stake in shares of iRadimed during the fourth quarter worth $1,594,000. Finally, R Squared Ltd bought a new stake in shares of iRadimed during the third quarter worth $308,000. 92.34% of the stock is currently owned by hedge funds and other institutional investors.
About iRadimed
(
Get Free Report)
iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.
In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
